AbbVie Q1 FY25: where the revenue came from and where it went
The whole income statement of AbbVie for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jan 1 – Mar 31, 2025
- Reported
- May 9, 2025
Revenue$13.3B
+8% year over year
Gross profit$9.3B
70% margin
Operating profit$3.7B
28% margin
Net profit$1.3B
10% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 13.3 | 100% | +8% |
| Skyrizi | 3.4 | 26% | |
| Neuroscience | 2.3 | 17% | |
| Rinvoq | 1.7 | 13% | |
| Oncology | 1.6 | 12% | |
| Other revenue | 1.3 | 9% | |
| Humira | 1.1 | 9% | |
| Aesthetics | 1.1 | 8% | |
| Other key products | 0.8 | 6% | |
| Cost of revenue | −4.0 | 30% | |
| Gross profit | 9.3 | 70% margin | +3pp |
| SG&A | −3.3 | 25% | −2pp |
| Other | −2.3 | 17% | +0pp |
| Operating profit | 3.7 | 28% margin | +5pp |
| Interest & other costs | −2.1 | ||
| Tax | −0.4 | ||
| Net profit | 1.3 | 10% margin | −1pp |
181 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest